Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged(NVOH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 9 days
PROFIT SINCE LAST BUY
-4.83% ▼
LAST CLOSE
$21.89
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NVOH

11/20/2026: NVOH (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) provides targeted exposure to Novo Nordisk's equity performance while neutralizing daily currency fluctuations via swap overlays. Its main strengths include a cost-effective 0.19% expense ratio and a specialized structure that eliminates foreign exchange noise for US investors. The fund functions primarily as a concentrated single-stock satellite holding rather than a diversified core investment. Key risks center on extreme single-stock concentration, regulatory pricing pressures, and lower secondary market liquidity. It suits growth-oriented investors looking for clean, currency-hedged access to a leading global pharmaceutical firm while monitoring execution spreads.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitProvides concentrated exposure to a high-growth global pharmaceutical leader focused on blockbuster metabolic therapies.
Momentum investorStrong fit while signal remains positiveAllows tactical participation in Novo Nordisk's price momentum when technical breakout conditions persist.
Value investorMixed fitValuation is often elevated due to strong secular growth expectations in obesity and diabetes treatment markets.
Dividend/Income investorMixed fitOffers a moderate dividend yield derived from underlying payouts, though capital appreciation is the primary objective.
Low-risk investorWeak fitConcentrated single-stock exposure introduces substantial company-specific and clinical trial risks.

Investor Profile

Ideal Investor Profile

Tactical or long-term investors seeking concentrated exposure to Novo Nordisk who specifically wish to neutralize USD/DKK currency risk.

Suitability

Best suited for sophisticated retail or advisory investors comfortable with single-stock risk and lower secondary market liquidity.

Risk Profile

Risk factorLevelWhy it matters
VolatilityMedium / highSingle-stock concentration leads to sharp price swings relative to diversified market baskets.
Market riskHighPerformance relies entirely on the market sentiment and business execution of a single underlying company.
ConcentrationHighThe portfolio is essentially 100% exposed to Novo Nordisk, offering zero sector or stock diversification.
Tracking/expenseLowDerivative swap execution costs and currency tracking error are minimal given the 0.19% expense ratio.
LiquidityMedium / highLow assets under management and modest trading volume can result in wider spreads during market stress.
Business/sector qualityLowNovo Nordisk is a world-class pharmaceutical entity with robust balance sheet metrics and market leadership.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

Exhibits volatility characteristic of a single high-growth pharmaceutical stock, amplified by concentrated positioning.

Market Risk

Vulnerable to equity market sell-offs, sector-specific healthcare corrections, and company-level pipeline or earnings setbacks.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
Single stockNovo Nordisk A/S Sponsored ADR Class B93.55Provides direct core economic exposure to Novo Nordisk's global pharmaceutical business.
Cash/collateralU.S. Dollar / Collateral Reserve6.45Maintains liquidity for daily operational costs, margin needs, and swap settlements.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type ETF
Historic Profit -46.31%
Avg. Invested days 18
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.